I kliniske forsøg har få patienter (< 0, 3%) behandlet med lumiracoxib udviklet perforationer, obstruktion eller blødninger (POB).
In clinical studies, few patients (< 0.3%) treated with lumiracoxib developed perforations, obstruction or bleeds (POBs).